Moneycontrol PRO
HomeNewsBusinessMarketsClosing Bell: Sensex ends 159 points higher, Nifty at 10,685; Infosys up 3%
Live now
auto refresh

Closing Bell: Sensex ends 159 points higher, Nifty at 10,685; Infosys up 3%

At the close of market hours, the Sensex ended up 159.06 points or 0.45% at 35513.14, while the Nifty was higher by 57.00 points or 0.54% at 10685.60.

November 27, 2018 / 15:36 IST
  • Closing Bell: Sensex ends 159 points higher, Nifty at 10,685; Infosys up 3%
    Moneycontrol.com
  • IndexPricesChangeChange%
    Sensex81,904.70355.97 +0.44%
    Nifty 5025,114.00108.50 +0.43%
    Nifty Bank54,809.30139.70 +0.26%
    Nifty 50 25,114.00 108.50 (0.43%)
    Fri, Sep 12, 2025
    Biggest GainerPricesChangeChange%
    Bharat Elec399.3014.15 +3.67%
    Biggest LoserPricesChangeChange%
    Eternal321.40-6.70 -2.04%
    Best SectorPricesChangeChange%
    Nifty Metal9883.6090.65 +0.93%
    Worst SectorPricesChangeChange%
    Nifty FMCG56557.15-403.45 -0.71%


  • November 27, 2018 / 15:36 IST

    Market at Close

    It’s a green close for the market on Tuesday, with the Nifty ending well above 10,650-mark.

    A rally among PSU banks, energy names as well as IT boosted the market. In the broader market, the Nifty Midcap index ended over half a percent higher.

    At the close of market hours, the Sensex ended up 159.06 points or 0.45% at 35513.14, while the Nifty was higher by 57.00 points or 0.54% at 10685.60. The market breadth was narrow as 1238 shares advanced, against a decline of 1320 shares, while 161 shares were unchanged.

    Infosys, TCS, and BPCL were the top gainers, while Sun Pharma and Hero MotoCorp lost the most.

  • November 27, 2018 / 15:27 IST

    PNB gains 2%

    :Punjab National Bank shares gained 2.5 percent after the lender expects Rs 2,500 crore recovery from Essar Steel resolution.

  • November 27, 2018 / 15:19 IST

    Moody's has downgradedYes Bank's ratings and changed outlook to negative, reported CNBC-TV18.

  • November 27, 2018 / 15:12 IST

    Buzzing

    :63 Moons Technologies shares declined nearly 4 percent after the company sold major stake in its subsidiary to Japanese firm.

  • November 27, 2018 / 14:59 IST

    Zydus Cadila gets USFDA approval:

    Zydus Cadila has received the final approval from the USFDA to market Baclofen Tablets, 10 mg and 20 mg. It will be manufactured at the group’s formulations manufacturing facility at Baddi.

  • November 27, 2018 / 14:47 IST

    Monte Carlo Fashions buyback:

    A meeting of the Board of Directors of the company is scheduled to be held on November 30 to consider and approve the buyback of fully paid-up equity shares of the company.

  • November 27, 2018 / 14:16 IST

    Lupin gets EIR from USFDA:

    The company has received EIR (Establishment Inspection Report) on the completion of an inspection by the USFDA (United States Food & DrugAdministration) at its facility in Tarapur, Maharashtra.

  • November 27, 2018 / 13:42 IST

    MARKET UPDATE 

    | At 13:40 hrs IST, the Sensex is up 92.02 points or 0.26% at 35446.10, and the Nifty up 30.90 points or 0.29% at 10659.50. The market breadth is negative as 1111 shares advanced, against a decline of 1229 shares, while 124 shares were unchanged.

  • November 27, 2018 / 12:33 IST

    MARKET OUTLOOK |

    Global investment firm HSBC raised India rating to neutral from underweight as the key is investors' holdings are very low.

    "Valuations are more reasonable & we see continued strong earnings growth in 2019," the research house said, adding the lower oil prices for now are supportive of Indian equities.

    Oil prices fell more than 30 percent to trade around $60 a barrel in last more than a month, after rising over 40 percent to above $86 (on October 3, 2018), the highest level seen since November 2014.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347